Literature DB >> 28735187

Progress in targeting the BCL-2 family of proteins.

Thomas P Garner1, Andrea Lopez1, Denis E Reyna1, Adam Z Spitz1, Evripidis Gavathiotis2.   

Abstract

The network of protein-protein interactions among the BCL-2 protein family plays a critical role in regulating cellular commitment to mitochondrial apoptosis. Anti-apoptotic BCL-2 proteins are considered promising targets for drug discovery and exciting clinical progress has stimulated intense investigations in the broader family. Here, we discuss recent developments in small molecules targeting anti-apoptotic proteins and alternative approaches to targeting BCL-2 family interactions. These studies advance our understanding of the role of BCL-2 family proteins in physiology and disease, providing unique tools for dissecting these functions. The BCL-2 family of proteins is a prime example of targeting protein-protein interactions and further chemical biology approaches will increase opportunities for novel targeted therapies in cancer, autoimmune and aging-associated diseases.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28735187      PMCID: PMC5667545          DOI: 10.1016/j.cbpa.2017.06.014

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  58 in total

1.  Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.

Authors:  Mai Nguyen; Richard C Marcellus; Anne Roulston; Mark Watson; Lucile Serfass; S R Murthy Madiraju; Daniel Goulet; Jean Viallet; Laurent Bélec; Xavier Billot; Stephane Acoca; Enrico Purisima; Adrian Wiegmans; Leonie Cluse; Ricky W Johnstone; Pierre Beauparlant; Gordon C Shore
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-26       Impact factor: 11.205

2.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

3.  Direct and selective small-molecule activation of proapoptotic BAX.

Authors:  Evripidis Gavathiotis; Denis E Reyna; Joseph A Bellairs; Elizaveta S Leshchiner; Loren D Walensky
Journal:  Nat Chem Biol       Date:  2012-05-27       Impact factor: 15.040

4.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

5.  An Autoinhibited Dimeric Form of BAX Regulates the BAX Activation Pathway.

Authors:  Thomas P Garner; Denis E Reyna; Amit Priyadarshi; Hui-Chen Chen; Sheng Li; Yang Wu; Yogesh Tengarai Ganesan; Vladimir N Malashkevich; Emily H Cheng; Evripidis Gavathiotis
Journal:  Mol Cell       Date:  2016-07-14       Impact factor: 17.970

6.  Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer.

Authors:  Y Loriot; P Mordant; D Dugue; O Geneste; A Gombos; P Opolon; J Guegan; J-L Perfettini; A Pierre; L K Berthier; G Kroemer; J C Soria; S Depil; E Deutsch
Journal:  Cell Death Dis       Date:  2014-09-18       Impact factor: 8.469

7.  BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo.

Authors:  Longchuan Bai; Jianfang Chen; Donna McEachern; Liu Liu; Haibin Zhou; Angelo Aguilar; Shaomeng Wang
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

8.  Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer.

Authors:  Stephanie Berger; Erik Procko; Daciana Margineantu; Erinna F Lee; Betty W Shen; Alex Zelter; Daniel-Adriano Silva; Kusum Chawla; Marco J Herold; Jean-Marc Garnier; Richard Johnson; Michael J MacCoss; Guillaume Lessene; Trisha N Davis; Patrick S Stayton; Barry L Stoddard; W Douglas Fairlie; David M Hockenbery; David Baker
Journal:  Elife       Date:  2016-11-02       Impact factor: 8.140

9.  hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents.

Authors:  Elisa Barile; Guya D Marconi; Surya K De; Carlo Baggio; Luca Gambini; Ahmed F Salem; Manoj K Kashyap; Januario E Castro; Thomas J Kipps; Maurizio Pellecchia
Journal:  ACS Chem Biol       Date:  2016-12-27       Impact factor: 5.100

10.  Identification of an activation site in Bak and mitochondrial Bax triggered by antibodies.

Authors:  Sweta Iyer; Khatira Anwari; Amber E Alsop; Wai Shan Yuen; David C S Huang; John Carroll; Nicholas A Smith; Brian J Smith; Grant Dewson; Ruth M Kluck
Journal:  Nat Commun       Date:  2016-05-24       Impact factor: 14.919

View more
  33 in total

Review 1.  Physiological and pharmacological modulation of BAX.

Authors:  Adam Z Spitz; Evripidis Gavathiotis
Journal:  Trends Pharmacol Sci       Date:  2021-11-27       Impact factor: 14.819

Review 2.  Naturally derived indole alkaloids targeting regulated cell death (RCD) for cancer therapy: from molecular mechanisms to potential therapeutic targets.

Authors:  Rui Qin; Feng-Ming You; Qian Zhao; Xin Xie; Cheng Peng; Gu Zhan; Bo Han
Journal:  J Hematol Oncol       Date:  2022-09-14       Impact factor: 23.168

3.  Morpholine substituted quinazoline derivatives as anticancer agents against MCF-7, A549 and SHSY-5Y cancer cell lines and mechanistic studies.

Authors:  Ashish Ranjan Dwivedi; Vijay Kumar; Vikash Prashar; Akash Verma; Naveen Kumar; Jyoti Parkash; Vinod Kumar
Journal:  RSC Med Chem       Date:  2022-04-05

4.  Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity.

Authors:  Xuan Zhang; Dinesh Thummuri; Xingui Liu; Wanyi Hu; Peiyi Zhang; Sajid Khan; Yaxia Yuan; Daohong Zhou; Guangrong Zheng
Journal:  Eur J Med Chem       Date:  2020-02-27       Impact factor: 6.514

5.  Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL.

Authors:  Xuan Zhang; Dinesh Thummuri; Yonghan He; Xingui Liu; Peiyi Zhang; Daohong Zhou; Guangrong Zheng
Journal:  Chem Commun (Camb)       Date:  2019-12-05       Impact factor: 6.222

6.  Homogeneous Oligomers of Pro-apoptotic BAX Reveal Structural Determinants of Mitochondrial Membrane Permeabilization.

Authors:  Zachary J Hauseman; Edward P Harvey; Catherine E Newman; Thomas E Wales; Joel C Bucci; Julian Mintseris; Devin K Schweppe; Liron David; Lixin Fan; Daniel T Cohen; Henry D Herce; Rida Mourtada; Yael Ben-Nun; Noah B Bloch; Scott B Hansen; Hao Wu; Steven P Gygi; John R Engen; Loren D Walensky
Journal:  Mol Cell       Date:  2020-06-12       Impact factor: 17.970

7.  BH3-Dependent and Independent Activation of BAX and BAK in Mitochondrial Apoptosis.

Authors:  Paul S Jeng; Akane Inoue-Yamauchi; James J Hsieh; Emily H Cheng
Journal:  Curr Opin Physiol       Date:  2018-03-20

8.  Design, Synthesis, Anticancer Activity, and Solid Lipid Nanoparticle Formulation of Indole- and Benzimidazole-Based Compounds as Pro-Apoptotic Agents Targeting Bcl-2 Protein.

Authors:  Manar I Nagy; Khaled M Darwish; Safaa M Kishk; Mohamed A Tantawy; Ali M Nasr; Mona Qushawy; Shady A Swidan; Samia M Mostafa; Ismail Salama
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-01

9.  Effect of ABT-263 on Intestinal Fibrosis in Human Myofibroblasts, Human Intestinal Organoids, and the Mouse Salmonella typhimurium Model.

Authors:  Laura A Johnson; Eva S Rodansky; Anhdao Tran; Stephen G Collins; Kathryn A Eaton; Benjamin Malamet; Calen A Steiner; Sha Huang; Jason R Spence; Peter D R Higgins
Journal:  Inflamm Bowel Dis       Date:  2022-02-01       Impact factor: 7.290

Review 10.  Double agents of cell death: novel emerging functions of apoptotic regulators.

Authors:  Heather M Lamb
Journal:  FEBS J       Date:  2020-04-11       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.